Failure due to poor in vivo efficacy is a primary contributor to attrition during the development
of new chemotherapeutics. Lead optimization programs that in their quest for efficacy focus …

… program at Stony Brook University in 2005, where he is now a member of Professor Tonge’s
research group. His current research focuses on the enzymatic mechanism of FabI from …

The development of therapies for the treatment of neurological cancer faces a number of major
challenges including the synthesis of small molecule agents that can penetrate the blood-…

Isoniazid (INH), a frontline antitubercular drug, inhibits InhA, the enoyl reductase from
Mycobacterium tuberculosis, by forming a covalent adduct with the NAD cofactor. Here, we report …

The rise of multi-drug resistant (MDR) and extensively drug resistant (XDR) tuberculosis
around the world, including in industrialized nations, poses a great threat to human health and …

Structural and genetic studies indicate that the antibacterial compound triclosan, an additive
in many personal care products, is an inhibitor of EnvM, the enoyl reductase from …

Novel chemotherapeutics for treating multidrug-resistant (MDR) strains of Mycobacterium
tuberculosis (MTB) are required to combat the spread of tuberculosis, a disease that kills more …

The enoyl-acyl carrier protein reductase (ENR) is involved in bacterial fatty acid
biosynthesis and is the target of the antibacterial diazaborine compounds and the front-line …

Docking scoring functions are notoriously weak predictors of binding affinity. They typically
assign a common set of weights to the individual energy terms that contribute to the overall …

InhA, the enoyl-ACP reductase in Mycobacterium tuberculosis is an attractive target for the
development of novel drugs against tuberculosis, a disease that kills more than two million …